BioRestorative Therapies Inc(BRTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 5:05 AM ET (Korea 9/29 18:05)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -22.4 | Insider Own | 6.74% | Shs Outstand | 1.4M | Perf Week | -14.76% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.3M | Perf Month | -43.93% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 13.83% | Short Float | 0.9% | Perf Quarter | -68.78% |
| Income | -0.01B | P/S | 8.86 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.53 | Perf Half Y | -61.14% |
| Sales | 0.00B | P/B | 0.97 | EPS next 5Y | - | ROA | -147.75% | Short Interest | 0.01M | Perf YTD | -90.17% |
| Book/sh | 2.38 | P/C | 0.89 | EPS past 3/5Y | 24.33% 43.92% | ROE | -241.14% | 52W High | -93.32% ($34.60) | Perf Year | -91.92% |
| Cash/sh | 2.6 | P/FCF | - | Sales past 3/5Y | 44.27% 36.11% | ROIC | -365.43% | 52W Low | -5.52% ($2.44) | Perf 3Y | -92.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 25.62% | Gross Margin | 33.24% | Volatility(W/M) | 11.46% 8.44% | Perf 5Y | -99.21% |
| Dividend TTM | - | EV/Sales | -1.03 | Sales Y/Y TTM | -8.47% | Oper. Margin | -3975% | ATR (14) | 0.29 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.35 | EPS Q/Q | 80.98% | Profit Margin | -3089.55% | RSI (14) | 24.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.35 | Sales Q/Q | -7.32% | SMA20 | -19.4% ($2.87) | Beta | 0.81 | Target Price | $20 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/05/20 | SMA50 | -41.61% ($3.96) | Rel Volume | 2.25 | Prev Close | $2.55 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 10.81% -86.67% | SMA200 | -73.88% ($8.84) | Avg Volume(3M) | 0.02M | Price | $2.31 |
| IPO | 1999/6/28 | Option/Short | No/Yes | Trades | 1711 | Volume | 49,420 | Change | -9.41% |
🧬 BioRestorative Therapies () is a US clinical-stage regenerative medicine biotech developing drug candidates that use patients' own stem cells to treat disc pain and metabolic diseases. Its core pipeline includes BRTX-100 (in Phase 2) for chronic lumbar disc pain and ThermoStem (preclinical), which targets obesity and metabolic conditions.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded more than usual That is 225% of its average volume.
BRTX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $886. Peers typically go for $1,227.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.8%.
Tap to view numbers
It ranks #569 of 592 in the industry
Based on market cap of $3M.
JUNS#568 Jupiter Neurosciences Inc $3M PER - BRTX#569 BioRestorative Therapies Inc $3M PER - 
JAGX#570 Jaguar Health Inc $3M PER - 
XRTX#571 XORTX Therapeutics Inc $3M PER - 
VRAX#571 Virax Biolabs Group Ltd $3M PER - 
FAQ
What kind of company is BRTX?
BRTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BRTX?
The market cap of BRTX is approximately $3M, ranking 5,776 within its sector.
What is the 52-week high and low for BRTX?
BRTX has recorded a 52-week high of $34.60 and a low of $2.44.
